Expression and clinicopathological significance of notch signaling and cell-fate genes in biliary tract cancer

American Journal of Gastroenterology

Volumn 107, Issue 1, 2012, Pages 126-132

  Mazur, Pawel K ^a   Riener, Marc Oliver ^b   Jochum, Wolfram ^c   Kristiansen, Glen ^d   Weber, Achim ^d   Schmid, Roland M ^a   Siveke, Jens T ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 1BETA; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; TRANSCRIPTION FACTOR HES 1; TRANSCRIPTION FACTOR SOX9;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; CELL FATE; CONTROLLED STUDY; FEMALE; GALLBLADDER CARCINOMA; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BILIARY TRACT NEOPLASMS; CARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE NUCLEAR FACTOR 1-BETA; HOMEODOMAIN PROTEINS; HUMANS; MALE; MIDDLE AGED; RECEPTOR, NOTCH1; RECEPTOR, NOTCH2; RETROSPECTIVE STUDIES; SOX9 TRANSCRIPTION FACTOR;

EID: 84855456052     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.305     Document Type: Article

References (49)

1. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008; 48: 308-21. (Pubitemid 351975555)
2. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 33-42. (Pubitemid 43102075)
3. Ehebauer M, Hayward P, Arias AM. Notch, a universal arbiter of cell fate decisions. Science 2006; 314: 1414-5. (Pubitemid 44871939)
4. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009; 137: 216-33.
5. Geisler F, Nagl F, Mazur PK, et al. Liver-specific inactivation of Notch2, but not Notch1, compromises intrahepatic bile duct development in mice. Hepatology 2008; 48: 607-16.
6. Zong Y, Panikkar A, Xu J et al. Notch signaling controls liver development by regulating biliary diff erentiation. Development 2009; 136: 1727-39.
7. Li L, Krantz ID, Deng Y et al. Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nat Genet 1997; 16: 243-51.
8. Oda T, Elkahloun AG, Pike BL et al. Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nat Genet 1997; 16: 235-42.
9. Kageyama R, Ohtsuka T, Kobayashi T. The Hes gene family: repressors and oscillators that orchestrate embryogenesis. Development 2007; 134: 1243-51. (Pubitemid 46710809)
10. Kodama Y, Hijikata M, Kageyama R et al. The role of notch signaling in the development of intrahepatic bile ducts. Gastroenterology 2004; 127: 1775-86. (Pubitemid 39575856)
11. Mazur PK, Einwachter H, Lee M, et al. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA 2010; 107: 13438-43.
12. Miyamoto Y, Maitra A, Ghosh B et al. Notch mediates TGF alpha-induced changes in epithelial diff erentiation during pancreatic tumorigenesis. Cancer Cell 2003; 3: 565-76. (Pubitemid 36808651)
13. Chen H, Th iagalingam A, Chopra H et al. Conservation of the Drosophila lateral inhibition pathway in human lung cancer: a hairy-related protein (HES-1) directly represses achaete-scute homolog-1 expression. Proc Natl Acad Sci USA 1997; 94: 5355-60. (Pubitemid 27214787)
14. Ramdass B, Maliekal TT, Lakshmi S, et al. Coexpression of Notch1 and NFkappaB signaling pathway components in human cervical cancer progression. Gynecol Oncol 2007; 104: 352-61. (Pubitemid 46135657)
15. Ishimura N, Bronk SF, Gores GJ. Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. Gastroenterology 2005; 128: 1354-68. (Pubitemid 40712185)
16. Akiyama H, Chaboissier MC, Behringer RR et al. Essential role of Sox9 in the pathway that controls formation of cardiac valves and septa. Proc Natl Acad Sci USA 2004; 101: 6502-7. (Pubitemid 38586003)
17. Bastide P, Darido C, Pannequin J et al. Sox9 regulates cell proliferation and is required for Paneth cell diff erentiation in the intestinal epithelium. J Cell Biol 2007; 178: 635-48. (Pubitemid 47267275)
18. Foster JW, Dominguez-Steglich MA, Guioli S et al. Campomelic dysplasia and autosomal sex reversal caused by mutations in an SRY-related gene. Nature 1994; 372: 525-30. (Pubitemid 24368528)
19. Kent J, Wheatley SC, Andrews JE et al. A male-specific role for SOX9 in vertebrate sex determination. Development 1996; 122: 2813-22. (Pubitemid 26326513)
20. Lefebvre V, Huang W, Harley VR et al. SOX9 is a potent activator of the chondrocyte-specific enhancer of the pro alpha1(II) collagen gene. Mol Cell Biol 1997; 17: 2336-46. (Pubitemid 27133320)
21. Mori-Akiyama Y, Van den Born M, Van Es JH et al. SOX9 is required for the diff erentiation of paneth cells in the intestinal epithelium. Gastroenterology 2007; 133: 539-46. (Pubitemid 47187347)
22. Perl AK, Kist R, Shan Z et al. Normal lung development and function aft er Sox9 inactivation in the respiratory epithelium. Genesis 2005; 41: 23-32. (Pubitemid 40269719)
23. Antoniou A, Raynaud P, Cordi S et al. Intrahepatic bile ducts develop according to a new mode of tubulogenesis regulated by the transcription factor SOX9. Gastroenterology 2009; 136: 2325-33.
24. Lu B, Fang Y, Xu J et al. Analysis of SOX9 expression in colorectal cancer. Am J Clin Pathol 2008; 130: 897-904.
25. Blache P, Van de Wetering M, Duluc I et al. SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. J Cell Biol 2004; 166: 37-47. (Pubitemid 38931915)
26. Wang H, McKnight NC, Zhang T et al. SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells. Cancer Res 2007; 67: 528-36. (Pubitemid 46192189)
27. Zhao C, Bratthauer GL, Barner er R, et al. Immunohistochemical analysis of sox9 in ovarian Sertoli cell tumors and other tumors in the diff erential diagnosis. Int J Gynecol Pathol 2007; 26: 1-9. (Pubitemid 46036951)
28. Wehrli BM, Huang W, De Crombrugghe B et al. Sox9, a master regulator of chondrogenesis, distinguishes mesenchymal chondrosarcoma from other small blue round cell tumors. Hum Pathol 2003; 34: 263-9. (Pubitemid 36356679)
29. Coffinier C, Gresh L, Fiette L, et al. Bile system morphogenesis defects and liver dysfunction upon targeted deletion of HNF1beta. Development 2002; 129: 1829-38. (Pubitemid 34874198)
30. Coffinier C, Barra J, Babinet C, et al. Expression of the vHNF1/HNF1beta homeoprotein gene during mouse organogenesis. Mech Dev 1999; 89: 211-3. (Pubitemid 29528294)
31. Gudmundsson J, Sulem P, Steinthorsdottir V et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007; 39: 977-83. (Pubitemid 47185170)
32. Sun J, Zheng SL, Wiklund F et al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet 2008; 40: 1153-5.
33. Th omas G, Jacobs KB, Yeager M et al. Multiple loci identified in a genomewide association study of prostate cancer. Nat Genet 2008; 40: 310-5. (Pubitemid 351311773)
34. Rebouissou S, Vasiliu V, Th omas C et al. Germline hepatocyte nuclear factor 1alpha and 1beta mutations in renal cell carcinomas. Hum Mol Genet 2005; 14: 603-14. (Pubitemid 40309586)
35. Terasawa K, Toyota M, Sagae S, et al. Epigenetic inactivation of TCF2 in ovarian cancer and various cancer cell lines. Br J Cancer 2006; 94: 914-21.
36. Lazarevich NL, Cheremnova OA, Varga EV et al. Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors. Hepatology 2004; 39: 1038-47. (Pubitemid 38428943)
37. Winckler W, Weedon MN, Graham RR et al. Evaluation of common variants in the six known maturity-onset diabetes of the young (MODY) genes for association with type 2 diabetes. Diabetes 2007; 56: 685-93. (Pubitemid 46348464)
38. Hamilton SR, Aaltonen LA. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Digestive System. 1st edn. IARC Press: Lyon, 2000.
39. Riener MO, Bawohl M, Clavien PA et al. Rare PIK3CA hotspot mutations in carcinomas of the biliary tract. Genes Chromosomes Cancer 2008; 47: 363-7. (Pubitemid 351451790)
40. Signoretti S, Loda M. Defining cell lineages in the prostate epithelium. Cell Cycle 2006; 5: 138-41. (Pubitemid 43131146)
41. Vidal VP, Chaboissier MC, Lutzkendorf S et al. Sox9 is essential for outer root sheath diff erentiation and the formation of the hair stem cell compartment. Curr Biol 2005; 15: 1340-51. (Pubitemid 41097538)
42. Moellering RE, Cornejo M, Davis TN et al. Direct inhibition of the NOTCH transcription factor complex. Nature 2009; 462: 182-8.
43. Plentz R, Park JS, Rhim AD, et al. Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 2009; 136: 1741-49.e6.
44. Fan X, Mikolaenko I, Elhassan I et al. Notch1 and notch2 have opposite Effects on embryonal brain tumor growth. Cancer Res 2004; 64: 7787-93. (Pubitemid 39446911)
45. Mazur PK, Gruner BM, Nakhai H, et al. Identification of epidermal Pdx1 expression discloses diff erent roles of Notch1 and Notch2 in murine Kras(G12D)-induced skin carcinogenesis in vivo. PLoS One 2010; 5: e13578.
46. Riener MO, Stenner F, Liewen H et al. Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology 2009; 49: 1602-9.
47. Riener MO, Vogetseder A, Pestalozzi BC et al. Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract. Hum Pathol 2010; 41: 1558-65.
48. Riener MO, Fritzsche FR, Clavien PA et al. IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas. Hum Pathol 2009; 40: 1377-83.
49. Riener MO, Fritzsche FR, Soll C et al. Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas. Histopathology 2010; 56: 600-6.